U.S. markets close in 6 hours 12 minutes

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
As of 3:43PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap460.249M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)0.97
Earnings DateApr 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
98% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    Sinovac COVID-19 vaccine effective but some data lacking - WHO experts

    The COVID-19 vaccine produced by China's Sinovac Biotech is efficacious in preventing COVID-19 in adults under 60, but some quality data on the risk of serious adverse effects is lacking, World Health Organization experts have found. The independent experts on the WHO's Strategic Advisory Group of Experts (SAGE) reviewed Sinovac's CoronaVac jab from phase 3 clinical trials in China, Brazil, Indonesia, Turkey and Chile.

  • When It Comes to a Travel Restart All Vaccines Are Not Equal
    Bloomberg

    When It Comes to a Travel Restart All Vaccines Are Not Equal

    (Bloomberg) -- With the resumption of global travel on the horizon, some people are discovering that their choice of vaccine could determine where they’re allowed to go.Already, the European Union is planning to allow Americans vaccinated with shots approved by their drug agency to enter over the summer, European Commission president Ursula von der Leyen suggested in a New York Times interview Sunday.This means that those who have shots by Chinese makers like Sinovac Biotech Ltd. and Sinopharm Group Co. Ltd. are likely to be barred from entry for the foreseeable future, with stark consequences for global business activity and the revival of international tourism.As inoculation efforts ramp up around the world, a patchwork of approvals across countries and regions is laying the groundwork for a global vaccine bifurcation, where the shot you get could determine which countries you can enter and work in.For Chinese citizens who venture abroad regularly, and western nationals wanting to pursue business opportunities in the world’s second-largest economy, a dilemma is emerging about which shot to opt for. China so far recognizes only Chinese-made shots, and its vaccines are not approved in the U.S. or Western Europe.Hong Kong citizen Marie Cheung travels to mainland China regularly for her work with an electric vehicle company, a routine that’s been interrupted by lengthy mandated quarantine stays since the pandemic began.Of the two vaccine options available in the city -- one from Sinovac and another developed by Pfizer Inc. and BioNTech SE -- Cheung plans to sign up for Sinovac for easier movement in and out of the mainland. Meanwhile, her British husband will go for the Pfizer-BioNTech shot, she says to boost his chances of visiting family in the U.K.“For people who need to work in or return to mainland, the Chinese vaccine is the only option for them,” Cheung said. “Westerners will only choose the vaccine recognized by their home country.”For millions of people worldwide who can’t choose which vaccines they get, the risk of more places becoming selective about which shots they recognize, especially given the vaccines’ varying efficacy rates, creates the possibility that even fully inoculated, people’s travel could still be limited -- with consequences for international business activity and the tourism industry.What’s the Best Covid Vaccine? Why It’s Not So Simple: QuickTakeThe EU plans to introduce vaccine passes as of June, which will allow travel for those inoculated or recently recovered from Covid and are thus considered immune. According to the draft of the regulation -- subject to ongoing negotiations between EU governments and the European Parliament -- all vaccines approved by the bloc’s drugs regulator will be acceptable for travel, though EU members are “encouraged” to accept vaccines that have secured World Health Organization approval for emergency use and recognize certificates issued by non-EU nations. The final decision on which vaccines will be accepted rests on individual member states.“A global division of peoples based around vaccine adoption will only exacerbate and continue the economic and political effects of the pandemic,” said Nicholas Thomas, associate professor in health security at the City University of Hong Kong. “It will risk the world being divided into vaccine silos based on vaccine nationalism rather than medical necessity.”Mutual RecognitionMany countries have shut their borders amid the pandemic, some allowing entry only to citizens, and even then with weeks-long quarantines after arrival. While vaccines are seen as the way to remove those entry barriers, considerable uncertainty remains over how, or if, nations will differentiate the at least 11 shots available worldwide.Governments from China to Europe are discussing vaccine passports -- easily accessible and verifiable certifications stating that an individual has been inoculated -- but it’s unclear if countries will pursue universal recognition of all shots, or be selective on which they choose to recognize, particularly with the rise of virus variants and questions over whether the current crop of vaccines are as effective against them.China eased visa application requirements for foreigners who had been inoculated with Chinese shots in March, including the ability to skip Covid tests or fill out travel declaration forms. The country’s homegrown vaccines are only available in some countries, like Brazil, Pakistan and Serbia. You can’t get Sinovac or the other Chinese shots in the U.S.But in a sign that Beijing may be cognizant of the economic costs of being selective on vaccines, the Chinese embassy in Washington said this week that travelers who had taken certain western shots could still enter the country if they were departing from Dallas in Texas. State media has indicated that the Pfizer-BioNTech shot is likely to be approved mid-year.“We do think that it’s important to get a very high percentage of the community vaccinated and the best way to do that is to offer choice,” said Ker Gibbs, president of the American Chamber of Commerce in Shanghai. As a key market and source of business for companies around the world, China’s border restrictions -- among the world’s strictest -- have “had a major impact on our ability to conduct business,” he said.A Vaccine Passport Is the New Golden Ticket as the World Reopens“Just speaking with our members, mobility is a high priority for us both in terms of allowing our executives to come in and out of China, but also to have their dependents travel back to China,” Gibbs said. “That’s been a big problem.”China isn’t the only place that’s restricting access to people with certain vaccinations. Iceland currently omits Chinese and Russian vaccines from the list of those it approves for entry.The question of vaccine recognition is a key one for tourism-dependent countries, with the $9 trillion global travel industry effectively paralyzed since the pandemic began.China’s approach to this issue may impact their decision-making, as Chinese tourists have been among the biggest groups of foreign visitors to travel hot spots in Southeast Asia, Australia and New Zealand and capitals as far away as Paris before the pandemic.There were 155 million outbound tourists in 2019 spending more than $133 billion abroad, according to the China Tourism Academy, a government think tank and subsidiary of the Ministry of Culture and Tourism. While Indonesia, home to Bali, and Thailand have approved and are administering Chinese shots, New Zealand and Australia -- which has seen its relations with China deteriorate the past year over the virus and trade -- do not.“I don’t know how practical it will be for western countries to recognize Chinese vaccines given the geopolitical environment,” said Ether Yin, a partner at Trivium China, a Beijing-based consultancy. “But there won’t be a true resumption of global travel or economy without the inclusion of China, plus dozens of economies who used Chinese vaccines.”Katy Niu, a 26-year old Chinese citizen, is a skiing enthusiast and frequent traveler living in Beijing. It’s unclear whether she’ll be returning to international slopes like those in Japan’s Hokkaido anytime soon. Prior to the pandemic, she used to travel internationally at least three times a year, from shopping on Paris’s Champs Elysées to relaxing on a Southeast Asian beach.Niu hasn’t gotten a vaccine yet, saying she didn’t feel any urgency since she’s not currently able to travel -- and doesn’t see it opening up in the near future.“If other countries don’t recognize the Chinese vaccine, does that mean vaccination is not going to make a difference?” she said. “We are not offered a western vaccine anyways -- we don’t have a choice.”(Adds information on EU in 10th paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Reuters

    UPDATE 1-Brazil's COVID-19 vaccination program at risk due to 2nd dose no-shows

    Brazil’s COVID-19 vaccination program is being put at risk by people failing to show up for their second shot, with 1.5 million people missing appointments for the follow-up dose needed to maximize protection, according to the Health Ministry. Specialists say that is particularly concerning after a recent real-world study from Chile found that the Sinovac Biotech COVID-19 vaccine, which has accounted for some 80% of Brazil's program, is just 16% effective after one shot. “Without the two doses, we get neither full protection nor a long duration of protection,” Juarez Cunha, head of the Brazilian Society of Immunizations, told Reuters.